A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity
18h agoen
From the article
Conditions : Obesity; Elevated High-sensitivity C-reactive Protein (hsCRP) Interventions : Drug: NNC6022-0004; Drug: Placebo Sponsors : Novo Nordisk A/S Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Statins and blood pressure drugs changing health risks of obesity, study suggests
STAT·7d ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica
bmj.com·20d ago
Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us
doi.org·12d ago
Un estudio siguió a personas con prediabetes durante 21 años y encontró algo mejor que una pastilla
afsdp.org.pe·23h ago
Novo Nordisk: Schritt für Schritt
aktiencheck.de
Novo Nordisk Aktie: STEP-UP-Studie stützt Wegovy
aktiencheck.de
Comments
Sign in to join the conversation.
No comments yet. Be the first.